Novo Nordisk on Wednesday managed the unusual feat of seeing its stock price rise after reducing its earnings outlook. But ...

Not long ago the largest company by market capitalization in Europe, the evolution of the weight loss medicine market has ...

Novo Nordisk now expects sales to grow 13% to 21% in constant currencies this year, from 16% to 24% previously. Operating profit should grow 16% to 24% compared with a previous target of 19% to 27%.

We recently published a list of 21 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Novo ...

Zepbound is the preferred weight loss medicine vs. Wegovy and has consistently beaten the latter in U.S. weekly prescriptions ...

Following the sell-off, Lilly trades at a forward price-to-earnings (P/E) of 37 times 2025 analyst estimates, with a price-to ...

Express Scripts, Cigna, UnitedHealthcare, CVS Caremark and Optum Rx are among the payers that have added Yesintek to their ...

Meanwhile, Clorox, considered a recession-proof stock, has recently declined as the market rebounded, making it a potential gauge for the continuation of the bull market phase. Marriott's earnings ...